Victorian healthcare providers facing class actions on behalf of junior doctors have turned to one law firm to lead their defence. And that firm might be about to get a lot busier.
Are group costs orders a factor in deciding a bid to transfer a class action? Can the orders survive the move to an inhospitable state? These questions are to be decided by the High Court Wednesday, in a ruling that will clarify the relevance and reach of Victoria’s contingency fee regime.
A judge has consolidated two class actions against Insurance Australia over alleged misleading loyalty discounts and rejected the insurer’s objection to the inclusion of documents produced by ASIC in the first-filed case.
The Australian Securities and Investments Commission has taken Australia’s largest super fund to court over alleged delays in processing almost 7,000 death benefit claims, which the fund has blamed on COVID-19.
A judge has rejected claims from Super Retail Group’s former top lawyer that suppression orders over details of an alleged settlement should be lifted so she can respond to the company’s “defamatory” version of events in the media, calling her claims “a bare assertion”.
Mayfield Development is barred from bringing claims already traversed in a competition case by the ACCC that was thrown out by a court, NSW Ports has told an appeals court.
In a landmark ruling, the High Court has held the federal government must compensate Indigenous people in north-east Arnhem Land for mining operations, finding the government cannot escape its constitutional obligation to acquire property on ‘just terms’. The Commonwealth challenged a May 2023 Full Court decision finding it must compensate the Gumatj Clan or Estate…
The Uniting Church has asked the High Court to weigh in after an appeals court found insurer Allianz was not on the hook for claims of abuse at exclusive Sydney private school Knox Grammar.
The Port of Newcastle has lost its bid to move a lawsuit filed by Glencore Coal over $870,000 in alleged overcharged shipping fees to the Federal Court.
The High Court won’t hear Bayer’s appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company’s claim the decision has “profound” consequences for drug R&D.